Literature DB >> 25646282

Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4?

Daniel S Streetman1, Stephen M Stout2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25646282      PMCID： PMC4330133          DOI： 10.1503/cmaj.150030

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

1.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

2.  Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.

Authors:  Rhianna M Tuchscherer; Kavita Nair; Vahram Ghushchyan; Joseph J Saseen
Journal:  Am J Cardiovasc Drugs       Date:  2015-02       Impact factor: 3.571

3.  Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.

Authors:  Daniel Q Li; Richard Kim; Eric McArthur; Jamie L Fleet; David G Bailey; David Juurlink; Salimah Z Shariff; Tara Gomes; Muhammad Mamdani; Sonja Gandhi; Stephanie Dixon; Amit X Garg
Journal:  CMAJ       Date:  2014-12-22       Impact factor: 8.262

4.  Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012.

Authors:  Qiuping Gu; Ryne Paulose-Ram; Vicki L Burt; Brian K Kit
Journal:  NCHS Data Brief       Date:  2014-12

5.  Use of administrative data to estimate the incidence of statin-related rhabdomyolysis.

Authors:  James S Floyd; Susan R Heckbert; Noel S Weiss; David S Carrell; Bruce M Psaty
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

Review 6.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

7.  The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Authors:  L B Ramsey; S G Johnson; K E Caudle; C E Haidar; D Voora; R A Wilke; W D Maxwell; H L McLeod; R M Krauss; D M Roden; Q Feng; R M Cooper-DeHoff; L Gong; T E Klein; M Wadelius; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2014-06-11       Impact factor: 6.875

8.  Application of new cholesterol guidelines to a population-based sample.

Authors:  Michael J Pencina; Ann Marie Navar-Boggan; Ralph B D'Agostino; Ken Williams; Benjamin Neely; Allan D Sniderman; Eric D Peterson
Journal:  N Engl J Med       Date:  2014-03-19       Impact factor: 91.245

9.  Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions.

Authors:  Jamie L Fleet; Salimah Z Shariff; David G Bailey; Sonja Gandhi; David N Juurlink; Danielle M Nash; Muhammad Mamdani; Tara Gomes; Amit M Patel; Amit X Garg
Journal:  BMJ Open       Date:  2013-07-11       Impact factor: 2.692

10.  Phenotype standardization for statin-induced myotoxicity.

Authors:  A Alfirevic; D Neely; J Armitage; H Chinoy; R G Cooper; R Laaksonen; D F Carr; K M Bloch; J Fahy; A Hanson; Q-Y Yue; M Wadelius; A H Maitland-van Der Zee; D Voora; B M Psaty; C N A Palmer; M Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2014-06-04       Impact factor: 6.875
  10 in total
  1 in total

1.  Population-Based Study of Risk of AKI with Levetiracetam.

Authors:  Kevin Yau; Jorge G Burneo; Racquel Jandoc; Eric McArthur; Flory Tsobo Muanda; Chirag R Parikh; Ron Wald; Matthew A Weir; Amit X Garg
Journal:  Clin J Am Soc Nephrol       Date:  2018-12-11       Impact factor: 8.237
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.